Murilo Freitas – Page 17

FDA, USDA, EPA enhance efforts to reduce food loss and waste, welcome USAID to interagency collaborative

Murilo Freitas - 20:31, 29 de May de 2024224

FDA, USDA, EPA enhance efforts to reduce food loss and waste, welcome USAID to interagency collaborative
http://www.fda.gov/news-events/press-announcements/fda-usda-epa-enhance-efforts-reduce-food-loss-and-waste-welcome-usaid-interagency-collaborative

rss

FDA’s Reorganization Approved for Establishing Unified Human Foods Program, New Model for Field Operations and Other Modernization Efforts

Murilo Freitas - 15:28, 29 de May de 2024171

FDA’s Reorganization Approved for Establishing Unified Human Foods Program, New Model for Field Operations and Other Modernization Efforts
http://www.fda.gov/news-events/press-announcements/fdas-reorganization-approved-establishing-unified-human-foods-program-new-model-field-operations-and

rss

OptumHealth Care Solutions Recalls Nimbus II Infusion Pump Systems Under Recall by InfuTronix, LLC

Murilo Freitas - 04:00, 29 de May de 2024180

Nimbus II infusion pumps may experience one or more issues that can cause severe patient injury and death.

http://www.fda.gov/medical-devices/medical-device-recalls/optumhealth-care-solutions-recalls-nimbus-ii-infusion-pump-systems-under-recall-infutronix-llc

rss

Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Docetaxel Injection, USP Due to Potential Presence of Particulate Matter

Murilo Freitas - 04:00, 28 de May de 2024177

Sagent Pharmaceuticals today announced the voluntary nationwide recall of two lots of Docetaxel Injection, USP (80 mg per 8 mL multi-dose vials and 160 mg per 16 mL multi-dose vials). The product was distributed by Sagent Pharmaceuticals. Sagent has initiated this voluntary recall of Docetaxel Injec

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sagent-pharmaceuticals-issues-voluntary-nationwide-recall-docetaxel-injection-usp-due-potential

rss

FDA Approves First Interchangeable Biosimilar for Two Rare Diseases

Murilo Freitas - 22:06, 27 de May de 2024271

FDA Approves First Interchangeable Biosimilar for Two Rare Diseases
http://www.fda.gov/news-events/press-announcements/fda-approves-first-interchangeable-biosimilar-two-rare-diseases

rss

FDA Roundup: May 28, 2024

Murilo Freitas - 19:39, 27 de May de 2024182

FDA Roundup: May 28, 2024
http://www.fda.gov/news-events/press-announcements/fda-roundup-may-28-2024

rss

FDA Roundup: May 24, 2024

Murilo Freitas - 18:45, 23 de May de 2024232

FDA Roundup: May 24, 2024
http://www.fda.gov/news-events/press-announcements/fda-roundup-may-24-2024

rss

Vyaire Medical, Inc. Recalls the Twin Tube Due to The Potential of The Nozzle Separating During Patient Use

Murilo Freitas - 04:00, 22 de May de 2024188

Vyaire Medical recalls Twin Tube due to potential nozzle separation risk posing a choking hazard.

http://www.fda.gov/medical-devices/medical-device-recalls/vyaire-medical-inc-recalls-twin-tube-due-potential-nozzle-separating-during-patient-use

rss

Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine Hydrochloride Injection CarpujectTM Units and Labetalol Hydrochloride Injection, USP CarpujectTM Units Due to the Potential for Incomplete Crimp Seals

Murilo Freitas - 04:00, 21 de May de 2024171

Hospira, Inc., a Pfizer company (“Pfizer”), is voluntarily recalling the lots listed in the table below of Buprenorphine Hydrochloride Injection CarpujectTM Units and Labetalol Hydrochloride Injection, USP CarpujectTM Units to the User level. The recall was initiated due to the potential for incompl

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/hospira-inc-issues-voluntary-nationwide-recall-buprenorphine-hydrochloride-injection-carpujecttm

rss

FDA Roundup: May 21, 2024

Murilo Freitas - 20:26, 20 de May de 2024200

FDA Roundup: May 21, 2024
http://www.fda.gov/news-events/press-announcements/fda-roundup-may-21-2024